Monthly Update: Novel imidazoline site ligands: Central & Peripheral Nervous Systems

References

• HAMILTON CA: The role of imidazoline receptors in blood pressure regulation. Pharmac. Ther. (1992) 54:231. Comprehensive review of imidazoline receptors and blood pressure homeostasis.
   Google Scholar
• RUFFOLO RR, RICE PJ, PATIL PN, HAMADA A, MILLER DD:Differences in the applicability of the Easson-Stedman hypothesis to the az and az adrenergic effects of phenylethylamines and imidazolines. Eur.J. Pharmacol. (1983) 86:471.
   PubMed Web of Science ®Google Scholar
• SASAKI S, TAKEDA K, LEE L-C, NAMURA M, IJICHI H:Different central active sites of two a2 adrenergic agonists: clonidine and guanfacine. j Hypertens. (1986) 4(Suppl.):S103
   Google Scholar
• ATLAS D, DIAMANT S, ZONNENSCHEIN R: Is the imida- zoline site a unique receptor? A correlation with do-nidine-displacing substance activity. Am. J. Hypertens. (1992) 5:83S. Review that assesses the evidence for CDS as an endogenous ligand for imidazoline sites.
   Google Scholar
• HAMILTON CA: Adrenergic and nonadrenergic effects of imidazole and related antihypertensive drugs in the brain and periphery. Am. J. Hypertens. (1992) 5:58S.
   PubMed Web of Science ®Google Scholar
• BOUSQUET P: Recent advances in knidazoline receptor research. Exp. Opin. Invest. Drugs (1995) 4(5):431–442. A recent review that assesses the status of imidazoline site research.
   Google Scholar
• COUPRY I, PODEVIN RA, DAUSSE J-P, PARINI A: Evidencefor imM•zoline binding sites in basolateral membranes from rabbit kidney. Biochem. Biophys. Res. Comm. (1987) 147:1055.
   PubMed Web of Science ®Google Scholar
• DE VOS H, BRICCA G, DE KEYSER J, DE BACKER J-P,BOUSQUET P, VAUQUELIN G: Imidazoline receptors, non-adrenergic idazoxan binding sites and a2-adreno-ceptors in the human central nervous system. Neurosci-ence (1994) 59:589.
   PubMedGoogle Scholar
• MICHEL M, ERNSBERGER P: Keeping an eye on the I site:imidazoline preferring receptors. Trends Pharm. Sci. (1992) 13:369.
   PubMed Web of Science ®Google Scholar
• ERNSBERGER P: Heterogeneity of imidazoline bindingsites. Proposed II. and 12 subtypes. Fundam. Gin. Phar-macol. (1992) 6\(Suppl. 1):55S.
   Google Scholar
• ERNSBERGER P, DAMON l'H, GRAFF LM, SCHAFER SG, CHRISTEN MO: Moxonidine, a centrally acting antihy-pertensive agent, is a selective ligand for 11-imidazoline sites. J. Pharm. Exp. Ther. (1993) 264:172.
   PubMed Web of Science ®Google Scholar
• LALIES M, NUTT D: A microdialysis study of the neuro-chemical effects in rat striatum of RX821039, a selective ligand for non-adrenoceptor idazoxan binding sites. Br. Pharmacol. (1993) 109:85P.
   Web of Science ®Google Scholar
• HUDSON AL, MALLARD NJ, NUTT DJ, CHAPLEO CB: Affin-ity and selectivity of 2-(2-lbenzo-furany1)-2-imidazoline for mammalian brain non-adrenoceptor idazoxan binding sites (12-sites). Br.J. Pharmacol. (1995) 114:411P.
   Web of Science ®Google Scholar
• MACKINNON AC, BROWN CM, REDFERN WS: RS 45041–190: a potent, selective ligand for 12 imidazoline recep-tors, with effects suggesting a possible role for these receptors in the modulation of appetite. Proceedings of the British Pharmacology Society, University of Kent at Can-terbury, April 5-7th, 1995.
   Google Scholar
• LIONE LA, NUTT DJ, LEWIS J, HUNTER J, TOWERS P,HUDSON AL:13142-(2-benzo-furatry1)-2-inaidazole: anew radioligand for the study of rabbit brain non-adreno-ceptor idazoxan binding sites (I2-sites). Br.J. Pharmacot (1995) 114:412P.
   Google Scholar
• MAC1UNNON AC, PARNES H, BROWN CM: PHIRS 45041–190: a potent and selective radioligand for 12 Wilda- zoline receptors. Proceedings of the British Pharmacology Society, University of Kent at Canterbury, April 5-7th, 1995. The above four abstracts describe novel ligands that selectively identify 12 sites. 38.
   Google Scholar
• MALLARD NJ, HUDSON AL, NUTT DJ: Characterizationand autoradiographical lovAli7ation of non-adrenocep-tor idazoxan binding sites in the rat brain. Br. J. Phar-macol. (1987) 106:1018.
   Google Scholar
• CARPENE C, COLLON P, REMAURY A, CORDI A, HUDSON A, NUTT D, LAFONTAN M: Inhibition of amine oxidase activity by derivatives that recognize imidazoline 12 sites. J. Pharmacol. Exp. Ther. (1995) 272:681. A recent paper that describes the relationship between 12 sites and monoamine oxidase.
   Google Scholar
• ERNSBERGER P, GIUUANO R, WIT LFTTE RN, REIS DJ: Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostra' ventrolateral me-dulla. J. Pharmacol. Exp. Ther. (1990) 253:408.
   PubMed Web of Science ®Google Scholar
• CODD EE, PRESS JB, RAFFA RB: a2-adrenoceptors vs. imidazoline receptors: implications for a2-mediated analgesia and other non-cardiovascular therapeutic uses. Life Sci. (1995) 56:63.
   Google Scholar
• TESSON F, PRIP-BUUS C, LEMIONE A, PEGORIER J-P, PARINI A: Subcellular location of im1d•7oline-guani-dium-receptive sites in human and rabbit liver. Major localization to the outer mitochondrial membrane. J. Biol. Chem. (1991) 266:155.
   Google Scholar
• RENOUD A, WIDDOWSON PS, CORDI A: PII1idazoxan binding to rabbit cerebral cortex recognizes multiple imklazoline I2-type receptors: pharmacological charac-terization and relationship to monoamine oxidase. Br. J. Pharmacol. (1993) 109:625.
   PubMedGoogle Scholar
• OLMOS G, GABILONDO AM, MIRALLES A, ESCRIBA PV, GARCIA-SEVILLA JA: Chronic treatment with the monoamine oxidase inhibitors clorgiline and par-gyline down regulates non-adrenoceptor [311lidazoxan binding in the rat brain. Br.J. Pharmacol. (1993) 108:597.
   PubMed Web of Science ®Google Scholar
• DALLEY JW, STANFORD SC: Contrasting effects of the imidazolan)e aradrenoceptor agonists, medetomid-ine, clonidine and UK 14,304 on extraneuronal levels of noradrenaline in the tut frontal cortex: evaluation using its vivo dialysis and synaptosomal uptake studies. Br, J. Pharmacol. (1995) 114:1717.
   PubMed Web of Science ®Google Scholar
• MENARGUES A, CEDO M, ARTIGA 0, OBACH R, GARCIA-SE VILLA JA: Modulation of food intake by alpha2 adreno-ceptor antagonists and 12 imklazoline drugs in rats: LSL 60101 as a novel and selective ligand for 12 hnidazoline sites. Br. J. Pharmacol. (1994) 111:298P.
   Google Scholar
• JACKSON HC, GRIN-EN IJ, NUTT DJ: Effects of hatgi•zoline (I2) site ligands on food and water intake in the rat. Proceedings of the British Pharmacology Society, University of Kent at Canterbury, April 5-7th, 1995.
   Google Scholar
• MACKINNON AC, LINTON C, BROWN CM: Inhibition ofmonoamine oxidase and (12) imidazoline affinity in rat kidney. Proceedings of the British Pharmacology Society, University of Kent at Canterbury, April 5-7th, 1995.
   Google Scholar
• ATLAS D: Clonidine displacing substance (CDS) and its putative imidazoline receptor. New leads for further divergence of alpha2 adrenergic receptor activity. Bio-chem. Pharmacol. (1991) 41:1541. A key review assessing the evidence for CDS.
   Google Scholar
• MEELEY MP, ERNSBERGER PR, GRANATA AR, REIS DJ: An endogenous clonidine displacing substance from bo-vine brain: receptor binding and hypotensive actions In the ventrolateral medulla. Life Sci. (1986) 38:1119.
   PubMed Web of Science ®Google Scholar
• BOUSQUET P, FELDMAN J, ATLAS D: Central cardiovas-cular effects of a non-catecholamlne endogenous ligand for clonidine receptors. J. Cardiovasc. Pharmacol. (1987) SuppL 12:S167.
   Google Scholar
• FELSEN J, ERNSBERGER P, MEELEY MP, REIS DJ: Clonicline displacing substance is biologically active on smooth muscle. Eur. J. Pharmacol. (1987) 142:453.
   PubMed Web of Science ®Google Scholar
• SYNETOS D, MONOLOPOULOS VG, ATLAS D, PIPIL1-SYN-1 h I OS E: Human plasma derived material with do-nidine displacing substance (CDS-like) properties contract the isolated rat aorta. J. Auton . Pharmacol. (1991) 11:343.
   PubMedGoogle Scholar
• SINGH G, HUSSAIN JF, MACKINNON AC, BROWN CM, KENDALL DA, WILSON VG: Evidence for the presence of a non-catecholamine, clonidine displacing substance in crude, methanolic extracts of bovine brain and lung. N-S Arch. Pharmacol. (1995) 351:17.
   PubMed Web of Science ®Google Scholar
• LI G, REGUNATHAN S, BARROW CJ, ESHRAGHI J, COOPER R, REIS DJ: Agmatine: an endogenous 'clonidine displac-ing substance' in the brain. Science (1994) 263:966.
   Google Scholar
• ATLAS D: Identifying clonidine displacing substance Science (1994) 266:462. Two key papers, the latter a critique of the former, concerning the chemical relationship of agmatine to CDS.
   Google Scholar
• PINTHONG D, WRIGHT IK, HANMER C, MILLNS P, MASON R, ICENDALL DA, WILSON VG: Agmatine recognizes a2-adrenoceptor binding sites but neither activates nor Inhibits a2-adrenoceptors. N-S Arch. Pharmacol. (1995) 351:10.
   PubMed Web of Science ®Google Scholar
• SZABO B, URBAN R, LIMBERGER N, STARKE K: Cardiovas-cular effects of agmatine, a donidine-displacing sub-stance in conscious rabbits. N-S Arch. Pharmacol. (1995) 351:268.
   PubMed Web of Science ®Google Scholar
• EISENACH JC: Alpha-2 agonists and analgesia. Exp. Opin. Invest. Drugs (1995) 3(10):1005–1010.
   Google Scholar